Triacetoxyethylsilane

We are Triacetoxyethylsilane CAS:17689-77-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

hemical Name:Triacetoxyethylsilane
CAS.NO:17689-77-9
Synonyms:[diacetyloxy(ethyl)silyl] acetate; Ethyltriacetoxysilane; 
(Triacetoxy)ethylsilane; Triacetoxy(Ethyl)Silane;
Molecular Formula:C8H14O6Si
Molecular Weight:234.27900
 
Physical and Chemical Properties:
Density:1.14;
Melting point:7-9oC;
Boiling point:107oC;
Flash point:106oC;
Index of Refraction:1.411;
 
Specification:
Appearance:Colorless or yellowish transparent liquid
Purity(GC):≥95.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:It is used as curing agent in acetoxy crosslinking RTV-1 sealant formulations. Within the curing reaction acetic acid is produced as a byproduct. Therefore, the corrosive reaction of the byproduct with substances like marble or iron has to be taken in consideration when using acetate crosslinkers.
It does not contain any additives such as catalysts, stabilizers or adhesion promotion agents. If required, these additives have to be added to the sealant formulation separately.

Triacetoxyethylsilane


Related News: As the global generic drug market booms and the international API industry accelerates its transfer to developing countries, China and India rely on cost advantages to rapidly grow into major API producers and exporters.4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)benzenesulfonyl chloride Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.2-cloro-3-fluoropiridina CAS:17282-04-1 What is the difference? Raw material refers to chemical compounds that are used as a base to make an API.42445-46-5 This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?

Related Products
Product Name
2-Phenoxyethylbromide View Details
2-Bromo-4-(trifluoromethyl)phenol View Details
5-(Trifluoromethyl)pyridin-2-amine View Details
Chloromethyldichloromethylsilane manufacturer N-methyl-2-(4-methylpiperazin-1-yl)-N-(4-nitrophenyl)acetamide manufacturer 4-(Trifluoromethoxy)chlorobenzene manufacturer 2-methoxy-6-methyl-1H-pyrimidin-4-one manufacturer 9-Fluorenylmethyl pentafluorophenyl carbonate manufacturer